IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
Public ClinicalTrials.gov record NCT06677710. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1B Study of IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Refractory Primary and Secondary Progressive Multiple Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open label, Phase 1b, multiple ascending dose, and dose-expansion study of IDP-023 administered in combination with interleukin-2 (IL-2) and ocrelizumab to evaluate the safety, tolerability, and biologic activity on autoreactive immune cells in patients with refractory progressive multiple sclerosis.
Study identification
- NCT ID
- NCT06677710
- Recruitment status
- Suspended
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 34 participants
Conditions and interventions
Conditions
- Multiple Sclerosis
- Primary Progressive Multiple Sclerosis (PPMS)
- Secondary Progressive Multiple Sclerosis (SPMS)
- Non-Active Secondary Progressive Multiple Sclerosis
- Non-Active SPMS
- Autoimmune Diseases of the Nervous System
- Nervous System Diseases
- Autoimmune Diseases
- Demyelinating Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, Central Nervous System (CNS)
Interventions
- IDP-023 Drug
- Ocrelizumab Drug
- Interleukin-2 Drug
- Cyclophosphamide Drug
- Fludarabine Drug
- Mesna Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 29, 2026
- Primary completion
- Dec 30, 2026
- Completion
- Dec 30, 2028
- Last update posted
- Apr 29, 2025
2026 – 2028
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University | Stanford | California | 94305 | — |
| University of Colorado Hospital | Aurora | Colorado | 80045 | — |
| AdventHealth Orlando - Adventist Health System/Sunbelt, Inc. | Orlando | Florida | 32803 | — |
| Kansas University Medical Center | Kansas City | Kansas | 66160 | — |
| Washington University in St. Louis | St Louis | Missouri | 63130 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Multiple Sclerosis trials
Other public records listing Multiple Sclerosis. Sorted by last update posted; newest first. Not a recommendation.
- NCT07779460: A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice Recruiting
- NCT07768761: Electrical Stimulation Exercise for Individuals With Lower Limb Paralysis Recruiting
- NCT07759115: Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility Study Not yet recruiting
- NCT05057676: Autoimmune Intervention Mastery Course Study Active, not recruiting
- NCT06233370: Acute Effects of Walking Exercise on Brain Functioning in Multiple Sclerosis Active, not recruiting
- NCT07115017: This Study Involves a Positron Emission Tomography (PET) Scan Using a New Investigational Radioactive Tracer, [18F]-FZTA, to Detect Inflammation in the Brain. The Tracer Will be Tested in Healthy Younger Adults and Individuals With Multiple Sclerosis. Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06677710, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 29, 2025 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06677710 live on ClinicalTrials.gov.